Read our Recent Headlines


Oct 18, 2018 by Dave Sobek

October 18 Biotech Update

We finally have some M&A in the sector but I am not convinced it will have a very broad effect. While it is not a small deal, the $2B or.

Share 0 Comments Read more
Oct 17, 2018 by Dave Sobek

October 17 Biotech Update

Yesterday was obviously a great day for the sector with everything higher and by a lot. It is not stunning to see some pullback from that move but if there.

Oct 16, 2018 by Dave Sobek

Briacell Interview

Chimera Research Group: What sets Briacell apart from other immuno-oncology approaches? Dr. William V. Williams, President and CEO of Briacell: Briacell is developing a novel cancer immunotherapy based on a.

Oct 15, 2018 by Dave Sobek

October 15 Biotech Update

Tell me if you heard this story before. Merger Monday and nothing happens in biotech. We have essentially run out of excuses as it was the political uncertainty and then.

Oct 12, 2018 by Dave Sobek

October 12 Biotech Update

Not a lot in terms of news but certainly in terms of action. The selloff has been brutal but I think we are much closer to a bottom than many.

Oct 10, 2018 by Dave Sobek

October 10 Biotech Update

I do not think there is much to say today outside of the obvious. The market is not looking good and we seem to be entering (or in the midst).

Oct 09, 2018 by Dave Sobek

October 9 Biotech Update

It was certainly not a great start to the week and the sector really needs a turnaround Tuesday to pan out. Interestingly, the pharma and large cap bios did OK.

More From All Reports

Introduction


Overview

Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.


The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate. Subscribe to Chimera Research Group and proceed with confidence.

Get Started!


      Join      

 Learn More